A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients

Summary

To determine the tolerance and antiviral response of two different doses of atevirdine mesylate (U-87201E) in symptomatic HIV-positive patients with CD4 counts of 50-350 cells/mm3, who also take zidovudine (AZT).

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications